Introduction
The prevalence of Streptococcus pneumoniae resistant to penicillin G and other antibiotics has increased worldwide at an alarming rate. 1, 2 Antibiotic resistance is a significant concern in the USA. For example, a recent survey has shown that 50.4% of 1476 clinically significant pneumococcal isolates were not susceptible to penicillin. 2 Furthermore, macrolide resistance was detected in 33% of the isolates, including 5% of penicillin-susceptible, 37% of penicillin-intermediate and 66% of penicillin-resistant strains. 2 Quinolone-resistant pneumococcal strains have also been reported with increasing frequency, particularly in Hong Kong and Canada. 3 Because of this worldwide increase in antibiotic resistance, there is a significant need for additional antimicrobial agents to treat infections caused by penicillin-intermediate and penicillin-resistant pneumococci. 1, 2 Although therapeutic modalities such as β-lactams, macrolides and quinolones are currently available, in view of the increasing resistance described above, an agent with a unique mechanism of action compared with these three antibiotic classes is desirable.
Daptomycin is a novel lipopeptide that exhibits rapid in vitro concentration-dependent bactericidal activity against most clinically significant Gram-positive bacteria. [4] [5] [6] Daptomycin is active against antibiotic-susceptible and -resistant strains, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and antibiotic-resistant pneumococci. The mode of action of daptomycin is unique; it is believed to kill Gram-positive bacteria by disrupting multiple aspects of bacterial plasma membrane function without penetrating into the cytoplasm. 4, 6 This study was designed to test the activity of daptomycin compared with that of amoxicillin, erythromycin, levofloxacin, linezolid, quinupristin/dalfopristin, penicillin G, teicoplanin and vancomycin against pneumococci using microdilution and time-kill methodologies. USA). Determination of MIC was carried out using microdilution techniques recommended by the NCCLS. 7 MuellerHinton broth was adjusted to contain 50 mg of calcium per litre for testing daptomycin. 4 Previous studies 4 have documented that the in vitro activity of daptomycin is enhanced by increased calcium concentrations, and that MICs thus obtained correlated well with favourable clinical outcome. 6 This calcium effect is not observed with other agent classes. 7 The initial calcium concentration in Mueller-Hinton broth was measured by Inductively Coupled Plasma Atomic Spectrometry (ICP), using model 61E ICP (Thermo Jarrell Ash Corporation, Franklin, MA, USA). Frozen microtitre trays containing appropriate concentrations of antibiotics were prepared by TREK Diagnostic Systems, Inc. (Westlake, OH, USA) and frozen at -70°C until use. Standard quality control strains, 7 including S. pneumoniae ATCC 49619, were included in each experiment.
Materials and methods
Time-kill activities were measured in duplicate, as described previously, for eight pneumococcal strains: two were penicillin susceptible and six penicillin resistant (of which three were erythromycin resistant and two levofloxacin resistant). 8 Mueller-Hinton broth was supplemented as described above, and antibiotic concentrations chosen were 4 × and 2 × MIC, and the MIC for each strain. Growth controls were included in each experiment. 8 The initial inoculum for each strain was within the range of 5 × 10 5 to 5 × 10 6 cfu/mL. Viability counts of antibiotic-containing cultures were carried out at 0, 1, 6, 12 and 24 h, as described previously. 8 Colony counts were carried out on plates yielding 30-300 bacterial colonies. The upper limit of sensitivity of colony counts was 300 cfu/mL. 8 Time-kill assays were analysed by determining the number of strains yielding a ∆log 10 cfu/mL of -1 (90% killing), -2 (99% killing) and -3 (99.9% killing) at 1, 6, 12 and 24 h, compared with counts at 0 h. Results are means of two assays. Bactericidal activity was defined as the lowest antibiotic concentration that reduced the original inoculum by ≥3 log 10 cfu/mL (99.9%) at each time period, and bacteriostatic activity was defined as a reduction of <3 log 10 cfu/mL in the inoculum concentration. 8 For time-kill testing with erythromycin, only strains with an erythromycin MIC of ≤1.0 mg/L were tested. Additionally, two strains with a levofloxacin MIC of 16 mg/L were excluded from levofloxacin time-kill assays.
Results
Results of MIC testing for the nine antibiotics against the 346 pneumococcal strains are presented in Table 1 . Dapto- Table 1 and were 0.125 mg/L (three strains), 0.25 mg/L (two strains) and 0.5 mg/L (three strains). Of these, two strains were penicillin susceptible and six were penicillin resistant. Results of the time-kill studies are summarized in Table 2 . Results are means of two assays. Daptomycin at 2 × MIC was bactericidal against seven of eight strains after 24 h, and at 4 × MIC was bactericidal against all eight strains tested. Significant bacterial killing was observed early, with 90% killing in the seven strains after 1 h of incubation with daptomycin at 2 × or 4 × MIC. In comparison, only quinupristin/ dalfopristin killed bacteria with similar rapidity after 1 h. Vancomycin, teicoplanin, levofloxacin and amoxicillin were bactericidal against 6-8 strains at 2 × MIC after 24 h. However, the rate of killing was slower compared with that of daptomycin. In addition, linezolid and erythromycin exhibited poor bactericidal activity compared with all the other agents tested, with bactericidal activity observed in only five of eight strains at 4 × MIC for both agents.
Discussion
In this study, the in vitro activity of daptomycin against pneumococci, measured by MIC determination and time-kill assays, was similar to results described previously. [4] [5] [6] Comparative activities of other agents active against Grampositive organisms such as vancomycin, linezolid and quinupristin/dalfopristin were similar to previous findings. 9, 10 Interestingly, compared with other antimicrobial agents predominantly active against Gram-positive organisms, daptomycin demonstrated very rapid kill kinetics, with significant killing of pneumococcal strains observed as early as 1 h after antibiotic exposure. In this study, only quinupristin/dalfopristin had comparable bactericidal activity. 8 This study supports a possible role for daptomycin in treating infections caused by antibiotic-susceptible and -resistant pneumococci, irrespective of the susceptibility of the given strain to β-lactams, macrolides or quinolones. Further studies are warranted on the bactericidal activity of daptomycin against S. pneumoniae, including relationship of kill kinetics with protein binding and pharmacokinetic/pharmacodynamic properties.
